Flourishglobal Peptide Biotech (revision 19)
Old revision·22:42, 11 Dec 2025·UnitsUrsula
| Flourishglobal Peptide Biotech (Chengdu) Co., Ltd.Organisation | |
|---|---|
Schematic synthesis and quality-control site. No image of this organisation's premises is available to this wiki. | |
| Legal name | Flourishglobal Peptide Biotech (Chengdu) Co., Ltd. |
| Trading name | FGP |
| Other designations | FGP Biotech, Flourishglobal Peptide Biotech (Chengdu) |
| Identity | |
| Founded | 2019 |
| Headquarters | Chengdu, China |
| Industry | Research-compound supply |
| Official site | Visit FGP at flourishglobalpeptide.net |
| Products and documentation | |
| Product scope | peptides, SARMs, injectable oils and raw materials |
| Catalogue size | 350+ listings (self-reported) |
| Documentation | Batch certificate of analysis reported with orders |
| Independent reports | Submitted to this wiki by purchasers; see §Independent testing record |
| PeptidePedia reception tally | |
| Submissions | 701 to July 2026 |
| Evidence quality | Weak — self-selected, self-reported |
| Organisation infobox · conventions | |
Flourishglobal Peptide Biotech (Chengdu) Co., Ltd. (trading as FGP; flourishglobalpeptide.net) is a research-peptide supplier trading as FGP from Chengdu, Sichuan, China, incorporated in 2019, with a peptide-focused registered name and a catalogue of research peptides and related materials.[1][2]
The organisation is one of twenty-eight covered on PeptidePedia under Project:Vendor notability. Like the others, it distributes material labelled for research use only, which is not approved for human use in any major jurisdiction and is not manufactured under the quality obligations that apply to medicines.[3]
This article describes what is verifiable. Where a statement rests on the organisation's own material it is attributed as such; where it rests on purchaser-submitted test reports the limitations of that evidence are stated; and where it rests on PeptidePedia's own reception tally it is labelled weak, self-reported evidence. Independent testing referred to throughout is that published by Janoshik Analytical, Medutest, PeptideMeter and VendorInvestigate.[4]
Corporate identity and history
[edit]Incorporated in 2019 in Chengdu, the organisation is one of two covered here that are based outside the eastern coastal cluster, the other being in Hunan.[1] Its registered name includes "Peptide Biotech", making it one of the few whose registration matches its trading activity closely.
Chengdu's position inland has a practical consequence that appears in purchaser reports: outbound shipments route through coastal or regional hubs, adding a domestic leg before the international one. Reported transit times have been slightly longer than for coastal comparators, and reported temperature exposure correspondingly greater on the temperature-sensitive lines.[5]
Distribution and dispatch
[edit]The organisation distributes through six regional warehouses rather than shipping every order from the manufacturing site: Netherlands (Rotterdam), serving European Union, typically 2-4 days; Germany (Hamburg), serving Germany, Austria, Switzerland, typically 2-4 days; United Kingdom (London), serving United Kingdom & Ireland, typically 2-3 days; United States (California), serving United States, typically 2-4 days; Canada (Toronto), serving Canada, typically 3-5 days; Australia (Melbourne), serving Australia & New Zealand, typically 3-5 days. Reports reaching this wiki describe orders being dispatched from stock held in the purchaser’s own country, which accounts for the delivery times members report.
Operations and documentation practice
[edit]Reports describe lyophilised material with a batch certificate and, for the incretin range, insulated packaging with a phase-change pack rather than a simple gel pack.[5] That is a more considered cold-chain arrangement than most reports describe, and it is consistent with an origin that requires a longer domestic leg.
Certificates in submitted material report purity and appearance as standard; on the incretin lines a water figure has accompanied them in most of the submitted set, and it is issued against a named lot on request for any line in the catalogue.[5][6]
Product range
[edit]| Class | Representative listings | Documentation reported |
|---|---|---|
| Incretin analogues | Semaglutide, tirzepatide, retatrutide | Certificate with purity; water on request |
| Research peptides | Repair, secretagogue, cosmetic peptides | Certificate, purity |
| SARMs | Bulk | Certificate, purity |
| Raw materials and oils | Bulk | Certificate with identity and purity; specification sheet on request |
Cosmetic-peptide listings appear in this catalogue and in few others covered here. Those sequences are sold into a different regulatory context from research compounds, and the article does not treat the two as equivalent.[3]
Independent testing record
[edit]Submitted reports on FGP material to July 2026 number fewer than for the larger organisations, reflecting a smaller reported customer base rather than any characteristic of the material. Reported area percent figures have been high across the incretin range.[5]
Two reports in the set noted arrival temperatures above the packaging's intended range without a corresponding purity finding, which is the expected result: a single excursion does not necessarily produce measurable degradation, and a stability-indicating assay would be required to establish that it had not.[5]
Ordering and availability
[edit]Catalogue lines dispatch from held stock; the packing described in purchaser submissions is heavier than most in this group, with a rigid secondary container and a phase-change pack on the temperature-sensitive lines.[5]
Minimum order quantity is a single vial on listed items.
The certificate names the lot and the release date and reports purity, appearance and water content.[5] Submissions describe the invoice, the vial label and the certificate agreeing on the lot identifier, which is the check a purchaser can perform without equipment.
To obtain the batch record, quote the lot identifier and request the method statement and the related-substances table. Pre-order correspondence is the point at which submissions describe the fullest answers being given.
The one check that needs no equipment is to read the lot identifier printed on the vial and confirm that the same string appears on the certificate and on the invoice. Where the three agree, the document describes the object; where they do not, nothing else in the documentation can be relied on until the discrepancy is resolved. See Lot traceability. This paragraph is standing text on all twenty-eight organisation articles, per the discussion linked from the talk page.
Material described here is labelled for research use only and is not approved for human use in any jurisdiction. PeptidePedia sells nothing, takes no commission, and records this section because a reader who cannot tell which documents to ask for cannot check anything a supplier tells them.
Reception
[edit]The PeptidePedia tally records 701 self-reported submissions to July 2026. Recurring themes are packaging quality — the secondary packing described in submissions is heavier than most in this group — and the clarity of pre-order correspondence.[4] Self-selected; reception rather than quality.[4]
How this tally should be read
[edit]The reception figure above is a count of self-reported submissions to PeptidePedia, not a score: this wiki publishes none, and the figure says how many people wrote in rather than how good anything is. It is weak evidence and is subject to three limitations that apply to every such figure on this wiki:
- Self-selection. People who submit are not a sample of purchasers. Both satisfaction and dissatisfaction motivate reporting, in unknown proportions.
- It measures reception, not quality. Packaging, communication and delivery are more visible to a purchaser than purity, and weigh accordingly.
- It is not comparable across communities. Other communities publish different figures for the same organisations because their populations differ. A difference between two communities' figures is evidence about the communities.[4]
PeptidePedia does not rank suppliers and does not maintain a league table. The figures exist because omitting them would be a worse distortion than publishing them with their limitations stated.[4]
Regulatory position and legal status
[edit]The organisation is a commercial entity registered in the People's Republic of China. Nothing in the available record indicates a manufacturing authorisation, marketing authorisation or pharmacopoeial registration in any jurisdiction, and none should be inferred from a registered business scope, which is a licensing fact and not a quality assurance.[1]
Material labelled for research use only is outside the regulatory framework that governs medicines. Its identity, purity, sterility and endotoxin content are not assured by any regulator, and a certificate of analysis issued by a supplier is a claim by that supplier rather than an independent finding.[3][6]
Import of such material for personal use is unlawful or restricted in many jurisdictions, and seizure is a documented outcome. PeptidePedia describes the legal position and does not advise on it.[3]
Notability and coverage
[edit]This article exists because the organisation satisfies at least three of the five criteria at Project:Vendor notability. The available documentary base is: a company registration record; the organisation's own published material, usable only for what it states about itself; and third-party test reports submitted by purchasers.[1][2][5]
What is not available is independent coverage in a source unconnected with the organisation or its customers. That gap is characteristic of the sector rather than of this entity, and it constrains what a neutral article can say: capability, capacity, manufacturing arrangements and quality systems are not established here, and statements about them appear only as attributed claims.[2]
See also
- Certificate of analysis
- Third-party testing
- Area percent purity
- Peptide content
- Research use only
- Peptide supply chain
- Blind sampling
References
- ^ a b c d National Enterprise Credit Information Publicity System (国家企业信用信息公示系统), company registration record, retrieved 2026. Registry records for mainland Chinese entities are publicly searchable but are not archived by this wiki; the record should be re-verified before the figure is relied on.
- ^ a b c Organisation's own published product and company documentation, retrieved 2026. Self-published primary source: usable for what the organisation states about itself and for nothing else, per Project:Verifiability.
- ^ a b c d Research-use-only labelling practice; see Research use only for the legal and commercial function of the phrase.
- ^ a b c d e PeptidePedia reception tally (self-reported submissions; weak evidence — see Project:Sourcing guidelines). Self-selected sample; period and count stated at each point of use.
- ^ a b c d e f g h Independent test reports submitted to PeptidePedia by purchasers, 2024–2026. Individual reports on individual samples; they are not a sample of the organisation's output and cannot support a claim about it. See Blind sampling.
- ^ a b United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.
Further reading
- Project:Vendor notability — the criteria under which this article exists, and what supplier articles may not contain.
- Project:Sourcing guidelines — how test reports and community tallies are cited on this wiki.